BSX stock in focus as Boston Scientific cuts 2026 outlook
BSX stock is in focus after Boston Scientific cut its 2026 adjusted profit outlook to $3.28–$3.32 per share from $3.34–$3.41, citing softer Watchman device demand, even as second-quarter earnings and revenue beat estimates and shares rose nearly 4% in premarket trading.
Key Takeaways
- Boston Scientific lowered 2026 adjusted EPS guidance to $3.28–$3.32 from $3.34–$3.41 after Watchman pressure.
- Organic sales growth guidance for 2026 was cut to 5%–6% from 6.5%–8%.
- Q2 adjusted profit of $0.86 and revenue of $5.44 billion both beat analyst estimates.
- A board-approved restructuring plan, set through 2029, targets cost cuts via supply-chain and manufacturing shifts.
- Premarket shares rose nearly 4% after the beat-and-cut report, per Reuters.
Why did Boston Scientific cut its 2026 outlook?
According to Reuters, the medical device maker trimmed its annual profit forecast on Wednesday because of pressure on its Watchman heart device business.
Watchman is a small implant used to help prevent stroke-causing blood clots in patients with atrial fibrillation. The company warned in May that uptake had been softer than expected.
Growth is being weighed down by a decline in standalone Watchman procedures as physicians increasingly combine the implant with other cardiac treatments in a single visit. Boston Scientific said it expects flat Watchman revenue growth in the second quarter and likely the third, even with continued uptake in combined procedures.
Full-year organic sales growth is now expected at 5% to 6%, down from a prior range of 6.5% to 8%. Analysts had been looking for annual adjusted profit of about $3.36 per share.
How did Q2 results compare with what Wall Street expected?
The Massachusetts-based company posted second-quarter adjusted profit of 86 cents per share, above the LSEG consensus of 83 cents. Quarterly revenue was $5.44 billion versus expectations of $5.36 billion.
Its cardiovascular unit reported sales of $3.62 billion, beating estimates of $3.58 billion. Shares were up nearly 4% in premarket trading after the company beat second-quarter results, Reuters reported.
Heading into the report, a Yahoo Finance preview noted the market was looking for roughly 5.9% year-on-year revenue growth, slowing from the prior year’s pace, and flagged an average analyst price target near $72 versus a then-recent share price around $45.55. For more investor context across wealth and markets, see our Net Worth & Wealth coverage.
What does the restructuring plan mean for BSX stock?
On July 21, Boston Scientific’s board approved a company-wide restructuring plan aimed at cutting costs and positioning the firm for future growth. The plan includes supply-chain optimization, production shifts between manufacturing sites, and organizational changes.
Those activities are expected to be largely completed by the end of 2029. The guidance cut comes ahead of that multi-year effort, which is why BSX stock traders are weighing near-term Watchman softness against longer-term efficiency goals.
Investors will next watch whether Watchman demand stabilizes after the expected flat stretch and whether restructuring savings offset softer organic growth in 2026.